These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 10459907

  • 1. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.
    Harnden P, Mahmood N, Southgate J.
    Lancet; 1999 Mar 20; 353(9157):974-7. PubMed ID: 10459907
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB.
    Mod Pathol; 2001 Apr 20; 14(4):267-72. PubMed ID: 11301341
    [Abstract] [Full Text] [Related]

  • 3. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
    Ramos D, Navarro S, Villamón R, Gil-Salom M, Llombart-Bosch A.
    Cancer; 2003 Apr 15; 97(8):1876-83. PubMed ID: 12673713
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, van der Kwast T, Montironi R.
    Cancer; 2008 Feb 01; 112(3):636-44. PubMed ID: 18072261
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF, Epstein JI.
    Am J Surg Pathol; 2007 Mar 01; 31(3):390-7. PubMed ID: 17325480
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K.
    Urology; 2004 Jul 01; 64(1):157-61. PubMed ID: 15245962
    [Abstract] [Full Text] [Related]

  • 14. Urothelial papilloma of the bladder. Clinical and biologic implications.
    Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, Bostwick DG.
    Cancer; 1999 Nov 15; 86(10):2098-101. PubMed ID: 10570437
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M, Kim B, Moon KC.
    Histopathology; 2019 Feb 15; 74(3):483-493. PubMed ID: 30286252
    [Abstract] [Full Text] [Related]

  • 20. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J, Chen X, Zhang Y, Li B, Sun J, Shen H, Kong C.
    Urol Oncol; 2012 Sep 15; 30(5):688-94. PubMed ID: 20888270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.